Mar. 4 at 1:37 PM
$ANAB Key items
- Intention to separate biopharma operations from substantial royalty assets on track for Q2 2026, potentially as early as late-April
- For the fourth quarter of 2025, Anaptys posted net income of
$49.6 million or
$1.79 per share, compared with a net loss of
$21.8 million or
$0.72 per share in the same quarter of 2024.
- For full year 2025, the company recorded a net loss of
$13.2 million, or
$0.46 per share, narrowing from a net loss
$145.2 million, or
$5.12 per share in 2024.
- Collaboration revenue rose sharply to
$108.2 million in Q4 2025 from
$43.1 million Q4 2024, and to
$234.6 million for the full year 2025 from
$91.3 million in 2024, driven by milestone payments and royalties from GSK's Jemperli and Vanda's Imsidolimab.
https://ir.anaptysbio.com/news-releases/news-release-details/anaptys-provides-update-business-separation-and-announces-fourth
